H.C. Wainwright analysts raised the price target for Halozyme Therapeutics on August 12, 2025.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
H.C. Wainwright analysts raised the price target for Halozyme Therapeutics on August 12, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Halozyme Therapeutics
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyH.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the top most undervalued biotech stocks to buy now. On August 6, H.C. Wain